
MOLECULAR ANALYSIS OF FRIEDREICH’S ATAXIA
IN MACEDONIAN PATIENTS Kocheva S1,2, Trivodalieva S1, Vlaski-Jekic S3, Kuturec M2, Efremov GD1,* *Corresponding Author: Professor Dr. Georgi D. Efremov, Macedonian Academy of Sciences
and Arts, Research Center for Genetic Engineering and Biotechnology, Aven Krste Misirkov 2,
POB 428, 1000 Skopje, Republic of Macedonia; Tel: +3892-120253; Fax: +3892-115434; E-mail:gde@manu.edu page: 61
|
RESULTS AND DISCUSSION
Representative electrophoregrams of PCR fragments from the amplification of GAA repeats in intron 1 of the frataxin gene in patients with FRDA and in healthy individuals are shown in Figure 1A and 1B, respectively. Polymerase chain reaction analyses of heterozygotes for expanded GAA alleles are shown in Figure 2. Of the 15 patients diagnosed with spinal cerebellar ataxia before 25 years of age, 14 (93.3%) were homozygous for the GAA expansion and all had two expanded alleles of same size and no detectable somatic instability. Only one patient with early onset of spinal cerebellar atax ia had two normal alleles, and this result excluded the diagnosis of FRDA. The 25 patients with late onset spinal cerebellar ataxia had two alleles in the normal size range (5-50 GAA repeats). Ten of these were heterozygotes and 15 were homozygous for normal alleles which excluded the diagnosis of FRDA.Molecular analysis of intron 1 of the frataxin gene in healthy individuals showed a range of GAA repeats from 5 to 50. Our results are concordant with already published data [1-4]. This long-range PCR protocol can be used as a diagnostic tool for FRDA and carrier detection.

Figure 1. Agarose gel electrophoresis of PCR products of intron 1 of the frataxin gene in healthy individuals (lanes 1-7) with different numbers of GAA repeats (A), and of seven patients with FRDA (lanes 1-7) (B); M: molecular weight marker.

Figure 2. Agarose gel electrophoresis of PCR products of patients (lanes 2, 5 and 6) and members of families with FRDA (lanes 1 and 3), showing the normal and expanded fragment (lanes 1 and 3); M: molecular weight marker.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|